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Abstract
Background: A high number of clinical T1 (cT1) stage renal cell carcinoma (RCC) is upstaged to pathological T3a 
(pT3a) stage on histopathological findings. Several study results show that there is no survival difference among those 
cT1 stage who are upstaged on histopathological findings to those who remain pT1 stage RCC.
Objectives: The objectives of this study were to assess any survival difference for cT1 stage renal cell carcinoma 
(RCC) which is upstaged to pT3a stage as compared to those which remain pT1 stage RCC on histopathological 
findings.
Materials and Methods: It was a retrospective cohort study looking at patient aged ≥18 years with cT1 RCC who 
underwent nephrectomy between January 2006 and December 2016. Patients were divided into two groups based on 
histopathological findings (pT1 vs. pT3a). Survival was analysed for the two groups using Kaplan–Meier method, and 
the difference in survival was calculated using log-rank model.
Results: The study included 187 patients. The mean age at presentation was 52.56 years, with 58.3% of the patients 
being male while 41.7% were female. The most common presentation was incidental diagnosis (50.3%). Overall 
5-year survival for cT1a and pT1a RCC was 68% while that for cT1a and pT3a RCC was 100%. There was no 
significant survival difference among the two groups (P = 0.316). The overall 5-year survival for cT1b and pT1b RCC 
was 81% while that for cT1b and pT3a was 65%. There was no significant survival difference among the two groups 
(P = 0.136).
Conclusion: We found no survival difference in cT1 RCC who were upstaged to pT3a on histopathology as compared 
to cT1 RCC-staged pT1 on histopathology.
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Introduction
According to the American Joint Committee on Cancer 
(AJCC) 8th edition,[1] clinical T1 (cT1) stage RCC is 7 
or <7 cm in size with no evidence of perinephric fat, 
renal sinus fat, pelvicalyceal system segmental or renal 
vessels or adrenal invasion on imaging modalities. 
Pathological T3a (pT3a) stage tumours are those tumours 
that have evidence of the involvement of perinephric fat 
or pelvicalyceal system or renal sinus fat or segmental/
renal vessels on pathological findings irrespective of 
tumour size. There is a significant survival difference 
among the various pT stage tumours and has been 
observed in multicentre cohort studies.[2,3] According to 
several studies, there is no significant survival difference 
between the renal cell carcinomas that are clinically and 
pT1 stage when compared to cT1 stage tumours but pT3a 
tumours.[4,5] The main aim of our study was to assess any 
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survival difference between cT1 stage RCC which was 
upstaged to pT3a on histopathological examination.
Materials and Methods
This study involved a retrospective collection of data 
from January 2006 to December 2016 following approval 
from the Institutional Review Board of Shaukat Khanum 
Cancer Hospital and Research Centre, Lahore. Data 
included demographic features, clinical, pathological and 
oncological variables. Computed tomography/magnetic 
resonance imaging images and histopathological reports 
were reviewed, and the AJCC 8th edition TNM staging 
system was used for clinical and pathological staging of 
the RCC retrospectively.
All those patients, who underwent surgery for renal 
tumours from January 2006 to December 2016 with 
proven histology of renal cell carcinoma having clinical 
stage T1 on initial diagnosis, were included in the study. 
Patients with histology other than RCC, nodal disease, 
metastatic disease or cT stage >1 were excluded from 
the study.
The patients were further divided into two groups. Group 1 
included those patients who had cT1 stage disease on 
initial diagnosis and pT1 stage on histopathological 
findings. Group 2 included those patients who had cT1 
stage but T3a histopathological stage. Data were analysed 
using SPSS 20 software, survival analysis was performed 
on the two groups using Kaplan–Meier method and any 
significant survival difference among the two groups was 
calculated using log rank model. P < 0.05 was considered 
significant.
Results
A total of 187 patients were included in our study. The 
mean age at presentation was 52.56 years. There was a 
male preponderance (n = 109, 58.3%), and 41.7% (n = 78) 
were female patients. The most common presentation was 
incidental diagnosis (50.3%), 30.5% of patients presented 
with pain and 18% of patients with haematuria. Other 
characteristics are summarised in Table 1.
Overall, 98 patients had cT1a stage tumour at presentation, 
among which 91 (92.9%) had pT1a stage tumour and 
7 (7.1%) had pT3a on histopathological findings. Median 
survival for cT1a and pT1a was 108 months while that 
for cT1a and pT3a tumour was 132 months. Using 
Kaplan–Meier analysis, 5-year overall survival for cT1a 
and pT1a RCC was 68% (standard error [SE]: 0.102) while 
that for cT1a and pT3a RCC was 100% [Figure 1]. There 
was no significant difference among the two groups in 
terms of overall survival using log-rank test (P = 0.316).
Similarly, 89 patients had T1b stage tumour at presentation, 
among which 76 (85.4%) had pT1b stage tumour and 
13 (14.6%) patients had pT3a tumour. Median time of 
survival for cT1b and pT1b was 120 months and that for 
cT1b and pT3a stage tumour was 72.3 months as described 
in Table 2.
The overall 5-year survival for cT1b and pT1b RCC 





Right renal tumour 93 (49.7)
Left renal tumour 94 (50.3)
Pain at presentation 57 (30.5)
Haematuria at presentation 35 (18)
Diagnosed incidentally 94 (50.3)
Figure 1: Survival function clinical T1a versus pathological T3a
JOURNAL OF CANCER & ALLIED SPECIALTIES 3
ORIGINAL ARTICLE J Cancer Allied Spec 2018;4(2):4
65% (SE: 0.17) using Kaplan–Meier model as shown in 
Figure 2. There was no significant survival difference 
among the two groups using log-rank test (P = 0.136). 
However, the projected difference in survival beyond 
5 years needs to be further looked into.
Incidentally diagnosed patients had 5-year survival of 82% 
while those who presented with symptoms had 5-year 
survival of 72%. There was no significant overall survival 
difference among the two groups (P = 0.119).
Discussion
We found that 7.1% and 14.6% of cT1a and cT1b RCC are 
upstaged to pT3a on pathological evaluation, respectively. 
However, there was no significant difference in the median 
or overall survival of the two groups over 5 years.
Most of the renal cancers are diagnosed incidentally,[6,7] 
and globally, the most common stage at presentations 
is cT1.[8] Overall and disease-free survival of cT1 RCC 
is good and can be managed with radical nephrectomy, 
nephron-sparing surgery or active surveillance.[9] As 
high as 30% of patients with cT1 stage tumour turn 
out to be pT3a stage tumour on histopathological 
findings. Since pT3a has an adverse survival outcome 
as compared to pT1 stage tumours,[2,3] a high number 
of patients with cT1 stage are upgraded on final 
histopathological findings.
In our study, the upstaging was noted in 7.1% and 14.6% 
of cT1a and cT1b tumours, respectively, which was 
similar to other international studies (5–15%).[5,10] The 
question, whether this upstaging of cT1 stage tumour 
on histopathological findings has any effect on survival 
outcomes, has been addressed in several studies and has 
concluded that there is no survival difference among 
the cT1 that is upstaged to pT3a as compared to pT1 
stage tumours.[11,12] We found that 5-year overall survival 
for cT1a and pT1a RCC was 68 ± 0.2% (SE: 0.102, CI 
95%) while that for cT1a and pT3a RCC was 100%. No 
significant difference was noted among the two groups in 
terms of overall survival using log-rank test (P = 0.316). 
Similarly, the overall 5-year survival for cT1b and pT1b 
RCC was 81 ± 0.121 % (SE: 0.062, confidence interval 
95%) while that for cT1b and pT3a was 65%, and there 
was no significant survival difference between the two 
groups (P = 0.136).
In our study, we noted 10.96% upstaging of cT1 stage 
renal cell cancer to pT3a stage and this upstaging is not 
associated with poor long-term outcomes. The number of 
patients in our study was much smaller, but our findings 
and literature review show similar results which demand 
further studies on this topic with a large number of 
patients.
Table 2: Median and overall survival
Clinical and pathological T stage Median survival (months) Overall 5‑year survival (%)
cT1a and pT1a 108 68
cT1a and P T3a 132 100
cT1b and pT1b 120 81
cT1b and pT3a 72.3 65
cT1b: Clinical T1b, pT3a: Pathological T3a
Figure 2: Survival function clinical T1b versus pathological T3a
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Conclusion
We found no survival difference in cT1 RCC who were 
upstaged to pT3a on histopathology as compared to cT1 
RCC-staged pT1 on histopathology.
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